相似文献
1
Structures of influenza A proteins and insights into antiviral drug targets.
Nat Struct Mol Biol. 2010 May;17(5):530-8. doi: 10.1038/nsmb.1779. Epub 2010 Apr 11.
2
Virulence and genetic compatibility of polymerase reassortant viruses derived from the pandemic (H1N1) 2009 influenza virus and circulating influenza A viruses.
J Virol. 2011 Jul;85(13):6275-86. doi: 10.1128/JVI.02125-10. Epub 2011 Apr 20.
3
Swine ANP32A Supports Avian Influenza Virus Polymerase.
J Virol. 2020 Jun 1;94(12). doi: 10.1128/JVI.00132-20.
4
Two amino acid residues in the N-terminal region of the polymerase acidic protein determine the virulence of Eurasian avian-like H1N1 swine influenza viruses in mice.
J Virol. 2024 Oct 22;98(10):e0129324. doi: 10.1128/jvi.01293-24. Epub 2024 Aug 30.
5
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.
6
Comparative study of the nucleotide bias between the novel H1N1 and H5N1 subtypes of influenza A viruses using bioinformatics techniques.
J Microbiol Biotechnol. 2010 Jan;20(1):63-70.
7
Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans.
J Virol. 2018 Sep 12;92(19). doi: 10.1128/JVI.01206-18. Print 2018 Oct 1.
8
Identification of influenza A nucleoprotein as an antiviral target.
Nat Biotechnol. 2010 Jun;28(6):600-5. doi: 10.1038/nbt.1638. Epub 2010 May 30.
9
[Swine influenza virus: evolution mechanism and epidemic characterization--a review].
Wei Sheng Wu Xue Bao. 2009 Sep;49(9):1138-45.
10
Eurasian Avian-Like Swine Influenza A Viruses Escape Human MxA Restriction through Distinct Mutations in Their Nucleoprotein.
J Virol. 2019 Jan 4;93(2):e00997-18. doi: 10.1128/JVI.00997-18.
引用本文的文献
1
A De Novo Luciferase Bioconjugate for the Cas13-Based Detection of Influenza A.
JACS Au. 2025 Jul 28;5(8):3914-3925. doi: 10.1021/jacsau.5c00576. eCollection 2025 Aug 25.
2
Dynamic adaptation mutations and pathogenic characterization of a mouse-adapted seasonal human H3N2 influenza virus.
Virol J. 2025 Jul 5;22(1):223. doi: 10.1186/s12985-025-02793-9.
3
A novel method to assess antibody-dependent cell-mediated cytotoxicity against influenza A virus M2 in immunized murine models.
Biosaf Health. 2024 Apr 17;6(3):178-185. doi: 10.1016/j.bsheal.2024.04.002. eCollection 2024 Jun.
4
Investigating Pb2 CAP-binding domain inhibitors from marine bacteria for targeting the influenza A H5N1.
PLoS One. 2025 Jan 28;20(1):e0310836. doi: 10.1371/journal.pone.0310836. eCollection 2025.
5
Discovering Influenza Virus Neuraminidase Inhibitors via Computational and Experimental Studies.
ACS Omega. 2024 Nov 25;9(49):48505-48511. doi: 10.1021/acsomega.4c07194. eCollection 2024 Dec 10.
6
Evolutionary analysis of Hemagglutinin and neuraminidase gene variation in H1N1 swine influenza virus from vaccine intervention in China.
Sci Rep. 2024 Nov 20;14(1):28792. doi: 10.1038/s41598-024-80457-4.
7
A comprehensive overview on the crosstalk between microRNAs and viral pathogenesis and infection.
Med Res Rev. 2025 Mar;45(2):349-425. doi: 10.1002/med.22073. Epub 2024 Aug 26.
8
Region-selective and site-specific glycation of influenza proteins surrounding the viral envelope membrane.
Sci Rep. 2024 Aug 16;14(1):18975. doi: 10.1038/s41598-024-69793-7.
9
An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil.
Sci Adv. 2024 Feb 23;10(8):eadk9004. doi: 10.1126/sciadv.adk9004.
10
Allopregnanolone targets nucleoprotein as a novel influenza virus inhibitor.
Virol Sin. 2023 Dec;38(6):931-939. doi: 10.1016/j.virs.2023.09.003. Epub 2023 Sep 22.
本文引用的文献
1
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
PLoS Pathog. 2010 Feb 26;6(2):e1000786. doi: 10.1371/journal.ppat.1000786.
2
Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein.
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1954-9. doi: 10.1073/pnas.0910715107. Epub 2010 Jan 19.
3
Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers.
Nature. 2010 Feb 4;463(7281):689-92. doi: 10.1038/nature08722.
4
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):882-7. doi: 10.1073/pnas.0909603107. Epub 2009 Dec 22.
5
Structure and function of the influenza A M2 proton channel.
Biochemistry. 2009 Aug 11;48(31):7356-64. doi: 10.1021/bi9008837.
6
Severe respiratory disease concurrent with the circulation of H1N1 influenza.
N Engl J Med. 2009 Aug 13;361(7):674-9. doi: 10.1056/NEJMoa0904023. Epub 2009 Jun 29.
7
The structure of a biologically active influenza virus ribonucleoprotein complex.
PLoS Pathog. 2009 Jun;5(6):e1000491. doi: 10.1371/journal.ppat.1000491. Epub 2009 Jun 26.
8
The directionality of the nuclear transport of the influenza A genome is driven by selective exposure of nuclear localization sequences on nucleoprotein.
Virol J. 2009 Jun 2;6:68. doi: 10.1186/1743-422X-6-68.
9
Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus.
J Am Chem Soc. 2009 Jun 17;131(23):8066-76. doi: 10.1021/ja900063s.
10
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.
Science. 2009 Jul 10;325(5937):197-201. doi: 10.1126/science.1176225. Epub 2009 May 22.
Zotero 插件